Renal Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major renal cell carcinoma markets reached a value of US$ 4.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 7.3 Billion by 2034, exhibiting a growth rate (CAGR) of 4.22% during 2024-2034.
The renal cell carcinoma market has been comprehensively analyzed in IMARC's new report titled "Renal Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Renal cell carcinoma refers to kidney cancer that develops in the lining of the proximal convoluted tubule, a section of the tiny tubes in the kidney that carry primary urine. This condition usually doesn't have any symptoms in its early stages. However, in time, individuals suffering from the ailment may experience blood in the urine, which may appear pink, red, or cola-colored, back pain, loss of appetite, unexplained weight loss, tiredness, fever, etc. The other common indications associated with this disease include increased abdominal mass, malaise, sleep disturbances, night sweats, high blood calcium levels, anemia, etc. The diagnosis of renal cell carcinoma is based on the patient's symptoms, medical history, and physical exam. A range of biochemical tests using urine and/or blood samples are also performed to provide adequate quantitative analysis of any differences in electrolytes. The other diagnostic procedures for detecting this disease include ultrasound, magnetic resonance imaging (MRI), computed tomography (CT) scans, etc.
The increasing cases of inherited genetic disorders, which cause DNA abnormalities and gene mutations, are primarily driving the renal cell carcinoma market. In addition to this, the rising prevalence of various risk factors, including advancing age, smoking, obesity, hypertension, certain medications, etc., is also bolstering the market growth. Furthermore, the inflating utilization of intravenous pyelograms to detect the presence of an unhealthy renal mass in the urinary tract is creating a positive outlook for the market. This minimally invasive method involves the injection of a contrasting dye into the patient's arm, which, over time, reaches the bladder and kidneys to provide a detailed image of the surrounding area. Additionally, the rising usage of nephron-sparing partial nephrectomy, since it allows the removal of a cancerous tumor or diseased tissue without damaging the healthy kidney cells, is acting as another significant growth-inducing factor. Moreover, several technological advancements in the field of percutaneous ablation therapies, including the launch of radiofrequency ablation and cryoablation, are improving treatment outcomes in patients while minimizing unwanted effects. This, in turn, is expected to drive the renal cell carcinoma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the renal cell carcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for renal cell carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the renal cell carcinoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the renal cell carcinoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the renal cell carcinoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current renal cell carcinoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the renal cell carcinoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the renal cell carcinoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the renal cell carcinoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of renal cell carcinoma across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of renal cell carcinoma by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of renal cell carcinoma by gender across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of renal cell carcinoma by type across the seven major markets?
How many patients are diagnosed (?2018-2034?) with renal cell carcinoma across the seven major markets?
What is the size of the renal cell carcinoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of renal cell carcinoma?
What will be the growth rate of patients across the seven major markets?
Renal Cell Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for renal cell carcinoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the renal cell carcinoma market?
What are the key regulatory events related to the renal cell carcinoma market?
What is the structure of clinical trial landscape by status related to the renal cell carcinoma market?
What is the structure of clinical trial landscape by phase related to the renal cell carcinoma market?
What is the structure of clinical trial landscape by route of administration related to the renal cell carcinoma market?
The renal cell carcinoma market has been comprehensively analyzed in IMARC's new report titled "Renal Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Renal cell carcinoma refers to kidney cancer that develops in the lining of the proximal convoluted tubule, a section of the tiny tubes in the kidney that carry primary urine. This condition usually doesn't have any symptoms in its early stages. However, in time, individuals suffering from the ailment may experience blood in the urine, which may appear pink, red, or cola-colored, back pain, loss of appetite, unexplained weight loss, tiredness, fever, etc. The other common indications associated with this disease include increased abdominal mass, malaise, sleep disturbances, night sweats, high blood calcium levels, anemia, etc. The diagnosis of renal cell carcinoma is based on the patient's symptoms, medical history, and physical exam. A range of biochemical tests using urine and/or blood samples are also performed to provide adequate quantitative analysis of any differences in electrolytes. The other diagnostic procedures for detecting this disease include ultrasound, magnetic resonance imaging (MRI), computed tomography (CT) scans, etc.
The increasing cases of inherited genetic disorders, which cause DNA abnormalities and gene mutations, are primarily driving the renal cell carcinoma market. In addition to this, the rising prevalence of various risk factors, including advancing age, smoking, obesity, hypertension, certain medications, etc., is also bolstering the market growth. Furthermore, the inflating utilization of intravenous pyelograms to detect the presence of an unhealthy renal mass in the urinary tract is creating a positive outlook for the market. This minimally invasive method involves the injection of a contrasting dye into the patient's arm, which, over time, reaches the bladder and kidneys to provide a detailed image of the surrounding area. Additionally, the rising usage of nephron-sparing partial nephrectomy, since it allows the removal of a cancerous tumor or diseased tissue without damaging the healthy kidney cells, is acting as another significant growth-inducing factor. Moreover, several technological advancements in the field of percutaneous ablation therapies, including the launch of radiofrequency ablation and cryoablation, are improving treatment outcomes in patients while minimizing unwanted effects. This, in turn, is expected to drive the renal cell carcinoma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the renal cell carcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for renal cell carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the renal cell carcinoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the renal cell carcinoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the renal cell carcinoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current renal cell carcinoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the renal cell carcinoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the renal cell carcinoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the renal cell carcinoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of renal cell carcinoma across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of renal cell carcinoma by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of renal cell carcinoma by gender across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of renal cell carcinoma by type across the seven major markets?
How many patients are diagnosed (?2018-2034?) with renal cell carcinoma across the seven major markets?
What is the size of the renal cell carcinoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of renal cell carcinoma?
What will be the growth rate of patients across the seven major markets?
Renal Cell Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for renal cell carcinoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the renal cell carcinoma market?
What are the key regulatory events related to the renal cell carcinoma market?
What is the structure of clinical trial landscape by status related to the renal cell carcinoma market?
What is the structure of clinical trial landscape by phase related to the renal cell carcinoma market?
What is the structure of clinical trial landscape by route of administration related to the renal cell carcinoma market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 RENAL CELL CARCINOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 RENAL CELL CARCINOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 RENAL CELL CARCINOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 RENAL CELL CARCINOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 RENAL CELL CARCINOMA - UNMET NEEDS
10 RENAL CELL CARCINOMA - KEY ENDPOINTS OF TREATMENT
11 RENAL CELL CARCINOMA - MARKETED PRODUCTS
11.1 List of Renal Cell Carcinoma Marketed Drugs Across the Top 7 Markets
11.1.1 Fotivda (Tivozanib) - AVEO Oncology/Kyowa Kirin
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Proleukin (Aldesleukin) - Clinigen/Novartis
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Sutent (Sunitinib) - Pfizer
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Inlyta (Axitinib) - Pfizer
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Lenvima (Lenvatinib) - Eisai Co Ltd/Merck & Co
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 RENAL CELL CARCINOMA - PIPELINE DRUGS
12.1 List of Renal Cell Carcinoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Pexastimogene Devacirepvec - SillaJen Biotherapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Batiraxcept - Aravive
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 CTX130 - CRISPR Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 XmAb819 - Xencor
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 CMN-001 - CoImmune
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. RENAL CELL CARCINOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. RENAL CELL CARCINOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 RENAL CELL CARCINOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Renal Cell Carcinoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Renal Cell Carcinoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Renal Cell Carcinoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Renal Cell Carcinoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Renal Cell Carcinoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Renal Cell Carcinoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Renal Cell Carcinoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Renal Cell Carcinoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Renal Cell Carcinoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Renal Cell Carcinoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Renal Cell Carcinoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Renal Cell Carcinoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Renal Cell Carcinoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Renal Cell Carcinoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Renal Cell Carcinoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Renal Cell Carcinoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Renal Cell Carcinoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Renal Cell Carcinoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Renal Cell Carcinoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Renal Cell Carcinoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Renal Cell Carcinoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Renal Cell Carcinoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Renal Cell Carcinoma - Access and Reimbursement Overview
16 RENAL CELL CARCINOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 RENAL CELL CARCINOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 RENAL CELL CARCINOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 RENAL CELL CARCINOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 RENAL CELL CARCINOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 RENAL CELL CARCINOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 RENAL CELL CARCINOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 RENAL CELL CARCINOMA - UNMET NEEDS
10 RENAL CELL CARCINOMA - KEY ENDPOINTS OF TREATMENT
11 RENAL CELL CARCINOMA - MARKETED PRODUCTS
11.1 List of Renal Cell Carcinoma Marketed Drugs Across the Top 7 Markets
11.1.1 Fotivda (Tivozanib) - AVEO Oncology/Kyowa Kirin
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Proleukin (Aldesleukin) - Clinigen/Novartis
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Sutent (Sunitinib) - Pfizer
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Inlyta (Axitinib) - Pfizer
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Lenvima (Lenvatinib) - Eisai Co Ltd/Merck & Co
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 RENAL CELL CARCINOMA - PIPELINE DRUGS
12.1 List of Renal Cell Carcinoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Pexastimogene Devacirepvec - SillaJen Biotherapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Batiraxcept - Aravive
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 CTX130 - CRISPR Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 XmAb819 - Xencor
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 CMN-001 - CoImmune
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. RENAL CELL CARCINOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. RENAL CELL CARCINOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 RENAL CELL CARCINOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Renal Cell Carcinoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Renal Cell Carcinoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Renal Cell Carcinoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Renal Cell Carcinoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Renal Cell Carcinoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Renal Cell Carcinoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Renal Cell Carcinoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Renal Cell Carcinoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Renal Cell Carcinoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Renal Cell Carcinoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Renal Cell Carcinoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Renal Cell Carcinoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Renal Cell Carcinoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Renal Cell Carcinoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Renal Cell Carcinoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Renal Cell Carcinoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Renal Cell Carcinoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Renal Cell Carcinoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Renal Cell Carcinoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Renal Cell Carcinoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Renal Cell Carcinoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Renal Cell Carcinoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Renal Cell Carcinoma - Access and Reimbursement Overview
16 RENAL CELL CARCINOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 RENAL CELL CARCINOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 RENAL CELL CARCINOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
